AGI-101H / National Cancer Institute  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AGI-101H / National Cancer Institute
NCT00716495: Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma

Terminated
1/2
5
Europe
AGI-101H Vaccine
AGIRx Ltd.
Melanoma
12/09
12/09

Download Options